Join Growin Stock Community!

Xencor, inc.XNCR.US Overview

US StockHealthcare
(No presentation for XNCR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XNCR AI Insights

XNCR Overall Performance

XNCR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XNCR Recent Performance

-4.72%

Xencor, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

XNCR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XNCR Key Information

XNCR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XNCR Profile

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Price of XNCR

XNCR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XNCR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.26
PB Ratio
1.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-73.20%
Revenue Growth (YoY)
25.13%
Profit Growth (YoY)
25.13%
3-Year Revenue Growth
9.33%
3-Year Profit Growth
9.33%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.29
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.26
PB Ratio
1.55
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-73.20%
Revenue Growth (YoY)
25.13%
Profit Growth (YoY)
25.13%
3-Year Revenue Growth
9.33%
3-Year Profit Growth
9.33%

  • When is XNCR's latest earnings report released?

    The most recent financial report for Xencor, inc. (XNCR) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XNCR's short-term business performance and financial health. For the latest updates on XNCR's earnings releases, visit this page regularly.

  • What is the operating profit of XNCR?

    According to the latest financial report, Xencor, inc. (XNCR) reported an Operating Profit of -53.63M with an Operating Margin of -189.92% this period, representing a decline of 306.95% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is XNCR's revenue growth?

    In the latest financial report, Xencor, inc. (XNCR) announced revenue of 28.24M, with a Year-Over-Year growth rate of -46.51%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does XNCR have?

    As of the end of the reporting period, Xencor, inc. (XNCR) had total debt of 187.75M, with a debt ratio of 0.21. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does XNCR have?

    At the end of the period, Xencor, inc. (XNCR) held Total Cash and Cash Equivalents of 54.36M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does XNCR go with three margins increasing?

    In the latest report, Xencor, inc. (XNCR) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -189.92%%, and net margin of -23.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess XNCR's profit trajectory and future growth potential.

  • Is XNCR's EPS continuing to grow?

    According to the past four quarterly reports, Xencor, inc. (XNCR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XNCR?

    Xencor, inc. (XNCR)'s Free Cash Flow (FCF) for the period is -52.85M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2.62% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of XNCR?

    The latest valuation data shows Xencor, inc. (XNCR) has a Price-To-Earnings (PE) ratio of -9.56 and a Price/Earnings-To-Growth (PEG) ratio of -3.42. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.